AstraZeneca invests $2 billion in Summit Therapeutics for ivonescimab partnership
AstraZeneca completed a $2 billion equity investment in Summit Therapeutics, giving it about a 12% ownership stake. The deal creates a collaboration with Daiichi Sankyo to test the bispecific antibody ivonescimab together with AstraZeneca’s ADC pipeline, starting with a pivotal trial in first‑line triple‑negative breast cancer. The partnership also targets lung, breast and gastrointestinal cancers using the Datroway ADC. The investment coincides with AstraZeneca’s new Cambridge R&D campus that will host nearly 2,000 researchers.
Why it matters
The $2 billion capital will fund global Phase 3 trials for ivonescimab combos, which the companies say should improve tumor regression and reduce toxicity for solid‑tumor patients.
Key facts
- 1AstraZeneca completed a $2 billion equity investment in Summit Therapeutics. qz.com
- 2The investment gives AstraZeneca roughly a 12% stake in Summit. qz.com
- 3AstraZeneca and Daiichi Sankyo will collaborate with Summit to evaluate ivonescimab together with Datroway in lung and breast cancer settings, beginning with a pivotal trial in first‑line triple‑negative breast cancer. qz.com
- 4The deal funds global Phase 3 clinical trials for ivonescimab in triple‑negative breast cancer and gastrointestinal cancers. geneonline.com
- 5Summit retains full development and commercial rights to ivonescimab. qz.com
- 6AstraZeneca's new R&D facility in Cambridge will house nearly 2,000 researchers. qz.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.